Pricing Log in Create free account

Inhibikase Therapeutics, Inc. (IKT) vs Prelude Therapeutics Incorporated (PRLD)

Inhibikase Therapeutics, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Prelude Therapeutics Incorporated are of similar size ($265.0M and $255.4M). Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −269.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Inhibikase Therapeutics, Inc. leads on 7 and Prelude Therapeutics Incorporated on 6.

Valuation

Metric IKT PRLD Biotechnology median
P/E n/m n/m 8.50
P/S 1,105.73 14.30 9.71
P/B 1.88 2.40 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 495.30 7.54 9.21
Earnings yield (26.06%) (22.39%) (33.15%)
Free cash flow yield (14.80%) (10.39%) (25.50%)

Profitability

Metric IKT PRLD Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (300.56%) 0.00%
Net margin 0.00% (269.75%) 0.00%
Free cash flow margin 0.00% (148.30%) 0.00%
Return on equity (51.96%) (57.73%) (56.36%)
Return on assets (48.04%) (39.76%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IKT PRLD Biotechnology median
Revenue growth (TTM) 110.93% — 6.02%
EPS growth (last fiscal year) 57.76% 23.21% 30.26%
Revenue growth, 5-year CAGR (42.21%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT PRLD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.82 4.07 4.72
Net debt to EBITDA 3.44 1.00 0.96

Dividend

Metric IKT PRLD Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IKT PRLD Biotechnology median
Market cap 255.35m 264.95m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack